Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Tectonic Operating Company, Inc.
Study ID
NCT07473700
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Hypertension, Pulmonary
  • Lung Diseases, Interstitial

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • TX000045 — DRUG
    Subcutaneous Injection.

Study Details

The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and tolerability of TX000045 in participants with PH-ILD.

Key Dates

Start date
Mar 30, 2026
Status verified
Mar 2026
Primary completion
Nov 21, 2027
Completion
Dec 11, 2027

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TX000045 300 mg
    Participants will receive subcutaneous (SC) injection of TX000045 at a dose of 300 milligrams (mg) every 4 weeks (Q4W) from Week 1 up to Week 13.

Primary Outcome Measure

Mean Change from Baseline in PVR up to 16 Weeks [ Time Frame: Baseline up to 16 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Scottsdale, ArizonaScottsdaleArizona85258-

Find similar trials in Scottsdale, AZ

By research site
Scottsdale, Arizona· Scottsdale, AZ

Related Studies